Podcasts about hcc

SummaryIn this episode, the hosts discuss various pressing issues in healthcare, including the recent increase in CMS investigations into Medicare risk adjustment data, the challenges faced by providers in complying with insurance requests, and the implications of Medicaid eligibility changes. They also delve into the role of GLP-1 medications in weight loss and the importance of patient advocacy in navigating healthcare decisions. The conversation emphasizes the need for healthcare professionals to engage in meaningful dialogue with insurers and to advocate for their patients' needs.TakeawaysThe increase in CMS investigators for Medicare risk adjustment data is significant.Providers have the right to push back against unrealistic insurance requests.Medicaid is a state program designed for low-income individuals and specific groups.Work requirements for Medicaid eligibility are being proposed, affecting millions.GLP-1 medications are becoming popular for weight loss but come with high costs.Patients should advocate for themselves and ask questions about their treatment plans.Insurance companies often request excessive documentation, creating administrative burdens.The healthcare system is facing challenges with compliance and documentation accuracy.Understanding the implications of HCC coding is crucial for providers.The long-term effects of new medications are still largely unknown.

The HCC Small Business Development Program (SBDP) is housed in Procurement Operations. The SBDP allows HCC to produce more effective small business participation and create opportunities relating to HCC contracting and procurement. “It's Your Business” was developed to highlight the local small businesses who are currently participating in contracting and procurement opportunities at HCC. Guest: Shearrard Thomas President & CEO, Signage One Host: Veronica Douglas, NIGP-CPP, CPPB, CTCM Manager, Small Business Development Program Record date:  May 27, 2025

IANR 2523 060725 Line Up4-6pm INTERVIEWSHere's the guest line-up for Sat, June 7, 2025 from 4 to 6pm CST on Indo American News Radio, a production of Indo American News (www.IndoAmerican-News.com). We are on 98.7 FM and you can also listen on the masalaradio app.By Monday, hear the recorded show on Podcast uploaded on Spotify, Apple Podcasts, Pocket Casts, Radio Public and Breaker. We have 6 years of Podcasts and have had thousands of hits.TO SUPPORT THE SHOW, SELECT FOLLOW ON OUR FREE PODCAST CHANNEL AND YOU'LL BE NOTIFIED OF NEW UPDATES.4:20 pm The Houston Community College system has 19 campuses spread all over the city and surrounding suburbs, offering a wide variety of courses leading to jobs in manyareas. We are joined today by the president of the beautiful and large Central Campus - the Jewel in the Crown of the HCC system – Dr. Butch Herod, who explains the programs offered there, and especially the wave of the future, Smart Technology.4:50 pm When we last had Rishi Bhutada of the Hindu American Foundation on the show, we went over thecontroversial Bluebonnet Learning lessons that the state is trying to impose on school districts. Now the Texas Legislature has sent a bill for Gov. Abbott's signature that would make it mandatory to have a 16 by 20 poster of the 10commandments prominently displayed in K through 12 classrooms. This is another encroachment on the separation of state and religion, so we asked Rishi to comment on this and what HAF may be doing to counter it.5:20 pm We all can think of many inventions and discoveries that have changed our world, from the wheel to the cell phone. We turned to Ashok Rao, a serial entrepreneur andrestauranteur - he owns Song Kran Thai restaurant in Uptown Park - to research out six compelling inventions and moments in time that have affected the way we live. Two weeks ago, he related the story of the Tulip Bubble and is back again today with the second episode of the fascinating History Talks series – the story of Ethylene.Also stay tuned in for news roundup, views, sports and movie reviews.      TO BE FEATURED ON THE SHOW, OR TO ADVERTISE, PLEASE CONTACT US AT 713-789-NEWS or 6397 or at indoamericannews@yahoo.comPlease pick up the print edition of Indo American News which is available all across town at grocery stores. Also visit our website indoamerican-news.com which gets 90,000+ hits to track all current stories.And remember to visit our digital archives from over 17 years. Plus, our entire 44 years of hard copy archives are available in the Fondren Library at Rice University.

Send us a textDr. Nikhil Kapila joins Dr. Michael Koren on this live MedEvidence! presentation. Dr. Kapila, a liver disease specialist, explains why we can't live without our liver. The doctors review what the liver does, what can cause damage to the liver, and what can go wrong when the liver suffers damage. They also discuss the importance of early testing, treatment options for some conditions, and the importance of clinical research in pushing liver health forward.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

In this episode, we look at three aspects of fitness for veterans: financial, mental and physical.  Host: Tim Stroud Guests: Chasity Wohlford Mental Health Peer Specialist/Veteran Navigator Easter Seals of Greater Houston Dexter Davis Director of Support and Giving PTSD Foundation of America Earl Lundy III Gym Manager Combined Arms Fitness Center Web Links: Veterans Voice website https://www.hccs.edu/support-services/veteran-affairs/veterans-voice/ HCC's Veteran and Military Affiliated Student Success Office (VMASS) https://www.hccs.edu/support-services/veteran-affairs/ Easter Seals of Greater Houston https://eastersealshouston.org/ PTSD Foundation of America https://ptsdusa.org/ Combined Arms https://www.combinedarms.us/ #Veterans #PTSD #PersonalFinance

Meditação de 31 de maio de 2025Leitura do devocional Manancial, publicação da União Feminina Missionária Batista do BrasilTítulo: Observando o agir de DeusTexto: Carol ViellLeitura e Edição: Samuel LimaBG: O grande amigo (165 HCC) - "What a Friend We Have in Jesus", com arranjo de Josh Snodgrass.

Petersfield Town Council unanimously appointed Chris Paige, Town Councillor for Rams Hill, as Petersfield’s new mayor at its meeting on 29 May 2025. Cllr Jamie Matthews, for Bell Hill, is the new Deputy Mayor.Outgoing mayor, Cllr Lesley Farrow, was thanked for all her work and she wished Chris every success.Chris is also the Council's Armed Forces Champion and is well known for his work with the military community veterans and the Royal British Legion. The Mayor’s charities for this year will be the Scouts and the Winton House Centre.Chris’s family - his wife Rebecca and two younger brothers, Martin and Jamie - spoke of their pride in Chris. Mike Waddington reports from the meeting . Report potholes to Hampshire County Council but only use problem/potholes or HCC's App.The Town Council papers are on line here: https://petersfieldtc.sharepoint.com/sites/Unrestricted/Shared%20Documents/Forms/AllItems.aspx?id=%2Fsites%2FUnrestricted%2FShared%20Documents%2FCOUNCIL%2FAGENDAS%2FScan%20Agendas%2F2025%2D26%2FAgenda%20Full%20Council%2029%2E05%2E25%20%2B%20docs%20%28non%2Dconfidential%29%2Epdf&parent=%2Fsites%2FUnrestricted%2FShared%20Documents%2FCOUNCIL%2FAGENDAS%2FScan%20Agendas%2F2025%2D26&p=true&ga=1See omnystudio.com/listener for privacy information.

Meditação de 30 de maio de 2025Leitura do devocional Manancial, publicação da União Feminina Missionária Batista do BrasilTítulo: Amor e perdãoTexto: Fabrício FreitasLeitura e Edição: Samuel LimaBG: O grande amigo (165 HCC) - "What a Friend We Have in Jesus", com arranjo de Josh Snodgrass.

In this episode, we explore HCC's English and Communications, including literature classes, virtual reality in speech offerings, and a recent Sign Language competition. Host: Amy Tan, Ph.D. Dean, English and Communications Guests: Erica Stevens, PhD Instructor, English James Duvall, MA Professor, Speech Communications Roxann Barrera-Coffman, M.Ed., CTD, ASLTA, BEI Basic Professor of American Sign Language and Interpreting & Transliterating Web Links: https://www.hccs.edu/programs/areas-of-study/liberal-arts--humanities/english/ https://www.hccs.edu/programs/areas-of-study/liberal-arts--humanities/communications/   #English #Communications #ASL

Meditação de 29 de maio de 2025Leitura do devocional Manancial, publicação da União Feminina Missionária Batista do BrasilTítulo: Você tem um melhor amigoTexto: Carol ViellLeitura e Edição: Samuel LimaBG: O grande amigo (165 HCC) - "What a Friend We Have in Jesus", com arranjo de Josh Snodgrass.

Meditação de 28 de maio de 2025Leitura do devocional Manancial, publicação da União Feminina Missionária Batista do BrasilTítulo: Quem sou eu?Texto: Carol ViellLeitura e Edição: Samuel LimaBG: O grande amigo (165 HCC) - "What a Friend We Have in Jesus", com arranjo de Josh Snodgrass.

Meditação de 27 de maio de 2025Leitura do devocional Manancial, publicação da União Feminina Missionária Batista do BrasilTítulo: Você cuida do corpo?Texto: Carol ViellLeitura e Edição: Samuel LimaBG: O grande amigo (165 HCC) - "What a Friend We Have in Jesus", com arranjo de Josh Snodgrass.

Meditação de 26 de maio de 2025Leitura do devocional Manancial, publicação da União Feminina Missionária Batista do BrasilTítulo: Qualidade nas relaçõesTexto: Carol ViellLeitura e Edição: Samuel LimaBG: O grande amigo (165 HCC) - "What a Friend We Have in Jesus", com arranjo de Josh Snodgrass.

Meditação de 25 de maio de 2025Leitura do devocional Manancial, publicação da União Feminina Missionária Batista do BrasilTítulo: Que amor é esse?Texto: Demilda LimaLeitura e Edição: Samuel LimaBG: O grande amigo (165 HCC) - "What a Friend We Have in Jesus", com arranjo de Josh Snodgrass.

Meditação de 24 de maio de 2025Leitura do devocional Manancial, publicação da União Feminina Missionária Batista do BrasilTítulo: O caminho perfeito e eternoTexto: Demilda LimaLeitura e Edição: Samuel LimaBG: O grande amigo (165 HCC) - "What a Friend We Have in Jesus", com arranjo de Josh Snodgrass.

Meditação de 23 de maio de 2025Leitura do devocional Manancial, publicação da União Feminina Missionária Batista do BrasilTítulo: Cura e restauraçãoTexto: Fabrício FreitasLeitura e Edição: Samuel LimaBG: O grande amigo (165 HCC) - "What a Friend We Have in Jesus", com arranjo de Josh Snodgrass.

Summer is upon us, and that means spending more time outside with family and friends. Whether you're hanging out in the back yard or strolling through a local park, talented landscapers help make those spaces beautiful and healthy. In this episode, we discover how HCC contributes to landscaping in Houston, and the role grants have played in our efforts. Host: Daniel Scholl HCC Financial Coach Guests: Mehmet Argin, Ph.D. Dean, Engineering Center of Excellence Archie Galang Owner, Archie's Garden Beds Matthew Barahona Agricultural Science Academy Student Web Links:  https://www.hccs.edu/programs/areas-of-study/science-technology-engineering--math/agricultural-sciences/ https://www.archiesgardenbeds.com/   #Landscaping #Agriculture

Meditação de 22 de maio de 2025Leitura do devocional Manancial, publicação da União Feminina Missionária Batista do BrasilTítulo: Vida e esperançaTexto: Demilda LimaLeitura e Edição: Samuel LimaBG: O grande amigo (165 HCC) - "What a Friend We Have in Jesus", com arranjo de Josh Snodgrass.

Meditação de 21 de maio de 2025Leitura do devocional Manancial, publicação da União Feminina Missionária Batista do BrasilTítulo: Amizade e féTexto: Demilda LimaLeitura e Edição: Samuel LimaBG: O grande amigo (165 HCC) - "What a Friend We Have in Jesus", com arranjo de Josh Snodgrass.

Meditação de 20 de maio de 2025Leitura do devocional Manancial, publicação da União Feminina Missionária Batista do BrasilTítulo: Olhar da consciênciaTexto: Rubens CordeiroLeitura e Edição: Samuel LimaBG: O grande amigo (165 HCC) - "What a Friend We Have in Jesus", com arranjo de Josh Snodgrass.

While on site at the 2025 Spring Meeting of the ABA Antitrust Law Section, the Our Curious Amalgam team recorded interviews with senior competition agency enforcers from all over the world, including Italy and Greece. In the first segment of this episode, Jaclyn Phillips interviews Saverio Valentino, Board Member of the Italian Competition Authority. Following that is the conversation between Panos Dimitrellos and Hara Nikolopoulou, Vice President of the Hellenic Competition Commission. Listen to this episode to hear what's been happening in their respective agencies, and what makes them happy outside of competition law. With special guests: Saverio Valentino, Board Member, Italian Competition Authority and Hara Nikolopoulou, Vice President, Hellenic Competition Commission Related Links: Italian Competition Authority Hellenic Competition Commission Hosted by: Alicia Downey, Downey Law LLC, Jaclyn Phillips, White & Case LLP, and Panos Dimitrellos, Secretariat Economists LLC

Meditação de 19 de maio de 2025Leitura do devocional Manancial, publicação da União Feminina Missionária Batista do BrasilTítulo: O prazer de viverTexto: Rubens CordeiroLeitura e Edição: Samuel LimaBG: O grande amigo (165 HCC) - "What a Friend We Have in Jesus", com arranjo de Josh Snodgrass.

Meditação de 18 de maio de 2025Leitura do devocional Manancial, publicação da União Feminina Missionária Batista do BrasilTítulo: Deus criou o amanhecerTexto: Rubens CordeiroLeitura e Edição: Samuel LimaBG: O grande amigo (165 HCC) - "What a Friend We Have in Jesus", com arranjo de Josh Snodgrass.

Meditação de 17 de maio de 2025Leitura do devocional Manancial, publicação da União Feminina Missionária Batista do BrasilTítulo: Cristo é sempre melhorTexto: Rubens CordeiroLeitura e Edição: Samuel LimaBG: O grande amigo (165 HCC) - "What a Friend We Have in Jesus", com arranjo de Josh Snodgrass.

Meditação de 16 de maio de 2025Leitura do devocional Manancial, publicação da União Feminina Missionária Batista do BrasilTítulo: Livre da opressãoTexto: Fabrício FreitasLeitura e Edição: Samuel LimaBG: O grande amigo (165 HCC) - "What a Friend We Have in Jesus", com arranjo de Josh Snodgrass.

Send us a textIn this Journal of Vascular and Interventional Radiology (JVIR) audio episode, JVIR blog Editor Peter Li, MD, MS, uses artificial intelligence (AI) platform ElevenLabs to produce a podcast discussion on the November 2024 JVIR paper, "Using Voxel-Based Dosimetry to Evaluate Sphere Concentration and Tumor Dose in Hepatocellular Carcinoma Treated with Yttrium-90 Radiation Segmentectomy with Glass Microspheres."Related resources:Read the original articleRead the blog entry, "Vox Voxel: Calculating Y90 Tumor Dose and Sphere Distribution with Voxel Dosimetry"SIR thanks BD for its generous support of the Kinked Wire.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology.Support the show

Meditação de 15 de maio de 2025Leitura do devocional Manancial, publicação da União Feminina Missionária Batista do BrasilTítulo: Jesus caminha em nossa direçãoTexto: Lidiane MachadoLeitura e Edição: Samuel LimaBG: O grande amigo (165 HCC) - "What a Friend We Have in Jesus", com arranjo de Josh Snodgrass.

Meditação de 14 de maio de 2025Leitura do devocional Manancial, publicação da União Feminina Missionária Batista do BrasilTítulo: Rendam graças ao SenhorTexto: Lidiane MachadoLeitura e Edição: Samuel LimaBG: O grande amigo (165 HCC) - "What a Friend We Have in Jesus", com arranjo de Josh Snodgrass.

This week's episode will be focusing on hepatocellular carcinoma (HCC). We will go over important details on assessing liver function, staging of HCC and loco-regional as well as systemic treatment options for HCC.

Time for a Would You Rather Wednesday edition of Glenn Clark Radio, lots and lots to go over on the program this morning. We'll reluctantly talk about the O's after another horrible loss last night as they get downed by the Twinkies in Minneapolis, falling 8 games below .500. We'll go over if there's anything to salvage the season, plus the latest from the Ravens as we continue to address the Justin Tucker release, plus some NBA Playoffs chatter, Stanley Cup playoffs as well after the Caps fell in OT to the Hurricanes last night. We'll see what's on Drew Forrester's mind this morning, since it's a Wednesday that means our guy from DrewsMorningDish.com and 105.7 The Fan will be hanging out in studio, we'll play some Would You Rather, talk Orioles, Justin Tucker, Caps hockey and of course get another installment of ‘Hanging On The Rim'. At 11am, we're going to check in with the Maryland Lacrosse team when we catch up with Terps goalkeeper Logan McNaney before Maryland's first round matchup this weekend as we talk to Logan about the season they've had, wearing the #1, and what needs to happen so they can make another National Title run. At 11:15am, we're going to talk baseball with Matt Snyder of the CBSSports.com, get his take on the Orioles, what has gone wrong, where we put the blame and what he would do with Mike Elias, Brandon Hyde and company. At 11:35am, we're going to meet another new Baltimore Raven in 6th round CB from Western Michigan, Bilhal Kone, go over his unique journey, from JUCO to NFL, where he gets inspiration and see what it meant to him to get that call from EDC and the Ravens on Draft Day. Then at 11:55am, we're going to catch up with the Head Coach of the Harford Community College Men's Lacrosse team, Aaron Varardi, before HCC hosts the championship and go for another National Title again this weekend!

There are now multiple phase 3 studies on combination transarterial chemoembolization (TACE) and immunotherapy showing a significant benefit over TACE alone. How do these findings change the hepatocellular carcinoma (HCC) treatment algorithm? In this multidisciplinary episode of the BackTable Podcast, Dr. Richard Finn (Medical Oncologist at UCLA) and Dr. Julius Chapiro (Interventional Radiologist at Yale University) join host Dr. Chris Beck to discuss immunotherapy, TACE, emerging trends in HCC treatment, and the future of the field.---This podcast is supported by an educational grant from Guerbet.---SYNPOSISThe doctors highlight the importance of high quality clinical data and the pivotal studies shaping current best practices. They explore the role of the different players on the multidisciplinary team and compare the oncologic and radiologic perspectives. Additionally, they discuss the synergy between TACE and immunotherapy, the criteria for selecting appropriate treatments, and the ongoing need for research and collaboration.---TIMESTAMPS00:00 - Introduction 03:35 - HCC from an Oncologic Perspective 05:33 - Radiological Perspective on Liver Cancer06:50 - Referral Patterns and Organizing a Multidisciplinary Approach18:01 - Explaining TACE and Variations in the Procedure27:27 - Choosing the Right Procedure for HCC36:13 - Making a Decision on Medical Treatment Candidacy 42:23 - Importance of Data Driven HCC Treatment, Practical Insights, and Studies to Know55:30 - Planning an Approach for a TACE Procedure01:02:26 - Final Thoughts and Future Prospects in Liver Cancer Treatment---RESOURCESBarcelona Staging System:https://www.ncbi.nlm.nih.gov/books/NBK569796/table/Ch3-t0001/TRACE Trial:https://pubs.rsna.org/doi/full/10.1148/radiol.211806PREMIERE Trial:https://www.gastrojournal.org/article/S0016-5085(16)34971-X/fulltextEMERALD-1 Trial:https://ascopubs.org/doi/10.1200/JCO.2024.42.3_suppl.LBA432LEAP O12 Study:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract

Send us a textThis recording features audio versions of May 2025 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Recurrent Portal Hypertension after Liver Transplant: Impact on Survival and the Role of Transjugular Intrahepatic Portosystemic Shunt Creation in Management ReadNontarget Hemangioma Size Reduction after Bleomycin–Ethiodized Oil Embolization of Primary Hepatic Hemangioma ReadMR–Guided Microwave Ablation for Patients with Cirrhosis Complicated by Small Hepatocellular Carcinoma ReadEmbolotherapy for Pulmonary Arteriovenous Malformations in the Pediatric Population with Hereditary Hemorrhagic Telangiectasias—A Retrospective Case Series ReadEffects of Prophylactic Coil Embolization of Pelvic Arteries on Surgical Outcomes in Hemodynamically Stable Patients with Complex Acetabular Fractures ReadPercutaneous Ablation versus Radiotherapy for Pain Related to Bone and Soft Tissue Malignancies: A Multipayor Database Analysis of Outcomes ReadJVIR and SIR thank all those who helped record this episode. To sign up to help with future episodes, please contact our outreach coordinator at millennie.chen.jvir@gmail.com.  Host:Sonya Choe, University of California Riverside School of MedicineAudio editor:Sonya Choe, University of California Riverside School of MedicineOutreach coordinator:Millennie Chen, University of California Riverside School of MedicineAbstract readers:Ahmed Alzubaidi, Wayne State University School of MedicineIpek Midillioglu, Western University of Health Sciences, College of Osteopathic MedicineNate Wright, Warren Alpert Medical School of Brown University Sanya Dhama, University of California Riverside School of MedicineTiffany Nakla, Touro University Nevada College of Osteopathic MedicineKalei Hering, Harvard Medical School SIR thanks BD for its generous support of the Kinked Wire.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology.Support the show

Hepatocellular carcinoma (HCC) disproportionately impacts underserved and minority populations, compounded by systemic barriers in care. These populations face increased risk factors yet often experience delayed diagnoses and limited access to specialists, leading to later-stage detection. In this episode, CANCER BUZZ speaks with Karen S. Waldrop, BSN, RN, OCN, ONN-CG, a GI oncology nurse navigator at UAB O'Neal Comprehensive Cancer, and Henry Rendon, a patient diagnosed with HCC in June 2023. Together, they share insights on the vital role of multidisciplinary teams and how nurse navigators can mitigate access barriers by improving patient outreach, facilitating access to care, and guiding patients through the complexities of the health care system.  “Karen, my nurse navigator, knew everything I was going through. She made sure everything was coordinated and ran smoothly. She communicated clearly and thoroughly every time. I never had to second-guess what was happening. She made sure I was prepared, not just once, but every step of the way.” - Henry Rendon, patient guest with HCC “At our institution, we have a clinic where the patient can see a medical oncologist, a liver medical physician, an interventional radiology specialist, a pharmacist… the whole gamut. If they need social work, we'll pull in social work. If they need palliative care, we'll pull in palliative care. And that's in one visit. For folks with transportation issues or those who live far away, it's truly the best way to get care.” - Karen S. Waldrop, BSN, RN, OCN, ONN-CG   Karen S. Waldrop, BSN, RN, OCN, ONN-CG GI Oncology Nurse Navigator UAB O'Neal Comprehensive Cancer Birmingham, Alabama   Henry Rendon Patient Guest, diagnosed with HCC Helena, Alabama   Additional Resources: Multidisciplinary HCC Care Effective Practices in Care Coordination - https://bit.ly/4lHTpbN HCC Education and Protocols to Advance Treatment through Integrated Collaboration - https://bit.ly/42GpatW Understanding practices and gaps in multidisciplinary hepatocellular carcinoma (HCC) care within the community oncology setting - https://bit.ly/3XT4k84 Building Multidisciplinary Care Capacity for People Impacted by Hepatocellular Carcinoma - https://bit.ly/44rgFUS  

En este episodio, repasamos los temas más críticos del día: • Wall Street rebota con esperanza: Los futuros suben tras rumores de negociaciones comerciales: $SPX +1.4%, $US100 +1.3%, $INDU +2.1%. Trump mantiene sus aranceles, pero está abierto a acuerdos. UE, Japón y Vietnam estarían entre los primeros países en la mesa de diálogo. • Occidental lidera captura de carbono: $OXY recibió aprobación de la EPA para iniciar el primer proyecto DAC con permiso Clase VI. STRATOS podrá almacenar hasta 500,000 toneladas métricas de CO₂ al año. Iniciará operaciones en 2025, con apoyo de BlackRock. • Trump impulsa minería de carbón: Firmará hoy una orden ejecutiva para revitalizar el carbón como fuente clave para centros de datos de IA. Acciones del sector suben fuerte: $BTU +7.6%, $ARLP +3.2%, $CNR +3.2%, $HCC +3.9%. • IBM lanza el z17 con IA integrada: $IBM presenta su nuevo mainframe con chip Telum II y coprocesador AI. Procesa hasta 450B inferencias por día. El sistema estará disponible desde el 8 de junio, con foco en seguridad, velocidad y decisiones inteligentes. Un episodio para entender cómo el comercio, la energía y la IA están redibujando el panorama económico global. ¡No te lo pierdas!

One Name - Part 6 Colossians 3:17 And whatever you do, in word or deed, do everything in the name of the Lord Jesus, giving thanks to God the Father through him. The exciting conclusion to 2025's Global Impact Celebration! Join us in worship and praise as we start today's service, including another performance from the HCC choir! After that, we've got even more updates from Global Impact ministry partners and an empowering message from Pastor Peter Kasirivu of Africa Renewal Ministries in Uganda. Then to wrap it all up, we'll announce this year's Faith Commitment Offering!

One name Part 5 Welcome to the kickoff service for 2025's Global Impact Celebration! This year's theme is 'One Name', and we start the weekend off with a powerful time of praise and worship, including the international flag processional, and a performance from the HCC choir. We'll hear updates from some of our ministry partners. Then Pastor Attila Csakany from Morning Star Ministries in Regina will share an inspiring message with us to wrap up tonight's service.

Colin and Andy go over the last week of HSR qualification, including a highly competitive HCC meet from the Fairgrounds.Want more from Indiana Runner, including our HSR Finals previews? Go to www.patreon.com/indianarunner

Do you ever wish you could be a fly on the wall at a tumor board meeting? In this episode of BackTable, we're excited to give you an insider's view of the real case discussions that take place during hepatocellular carcinoma (HCC) tumor boards. Host Dr. Zach Berman sits down with a multidisciplinary team, including Drs. Adam Burgoyne (medical oncologist), Heather Patton (hepatologist), Siddharth Padia (interventional radiologist), and Gabriel Schnickel (transplant and hepatobiliary surgeon). Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125743 --- This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific. --- SYNPOSIS The team walks through a range of diverse HCC cases, reviewing patient histories, imaging, and treatment options. They cover eight cases in total, each featuring patients with varying treatment histories, comorbidities, liver function, and lesion characteristics. For the full educational experience, we recommend watching the video format on our YouTube channel. --- TIMESTAMPS 00:00 - Introduction 00:47 - Case 1: Small Lesion in a Young Patient 05:01 - Case 2: Moderate Sized Lesion in an Older Patient 11:10 - Case 3: Multifocal HCC with Dominant Lesion 21:09 - Case 4: Dominant Lesion with Portal Hypertension 32:08 - Case 5: Ruptured Solitary Lesion 34:34 - Case 6: Rupture with Multifocal Lesions 44:08 - Case 7: Portal Vein Invasion 52:12 - Case 8: Metastatic HCC After Transplant --- RESOURCES CME Accreditation Information: https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf

Medical, surgical, radiation, and interventional oncology all play vital roles in delivering care to patients battling liver cancer. How do we optimize outcomes when so many specialties have something to offer the same patient? The answer is collaborative oncology. Dr. Robert Martin (Director of Surgical Oncology, University of Louisville) and pioneer in liver-directed therapies, joins host Dr. Sabeen Dhand to discuss a collaborative approach to oncology and recent advances in locoregional therapy. --- This podcast is supported by: RADPAD® Radiation Protection https://www.radpad.com/ --- SYNPOSIS Dr. Martin discusses the importance of a growth mindset in advancing medical techniques and fostering collaborations between specialists. He then shares insights into minimally invasive procedures, such as microwave ablation and irreversible electroporation (IRE). The doctors also touch on the evolution of liver cancer treatments, emphasizing the significance of clinical trials on the horizon. To conclude, Dr. Martin encourages young professionals in surgery and interventional radiology to stay open-minded, be life-long learners, and find synergistic ways to integrate new technologies into patient care. --- TIMESTAMPS 00:00 - Introduction 02:31 - Dr. Martin's Background and Career Path 06:18 - Evolution of Liver Directed Therapies 10:12 - Collaboration Between Specialties 18:34 - Clinical Trials and Emerging Therapies 36:08 - Advice for Young Professionals 39:15 - Conclusion --- RESOURCES Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of HCC: https://clinicaltrials.gov/study/NCT05953337?term=NCT05953337&rank=1 Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (INJECTABL-1): https://clinicaltrials.gov/study/NCT05688280 Immunophotonics, CIRSE, and Next Research Announce Innovative Phase 2/3 Clinical Trial: INJECTABL-3: https://immunophotonics.com/news/immunophotonics-cirse-and-next-research-announce-innovative-phase-2-3-clinical-trial-injectabl-3/

Is surgery truly the "cure" for hepatocellular carcinoma (HCC), and when is it a viable option? In this episode, Dr. Sabeen Dhand leads a roundtable discussion with interventional radiologist Dr. Siddharth Padia and transplant/hepatobiliary surgeons Dr. John Seal and Dr. Gabriel Schnickel, delving into the complexities of surgical treatments for HCC and the evolving landscape of liver resection and transplantation. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125741 --- This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific. --- SYNPOSIS The doctors begin by discussing how they manage patient expectations regarding both palliative and curative treatments, highlighting the risk of recurrent HCC as a new lesion. They then outline key factors that influence their recommendations for liver transplant versus resection, such as the extent of underlying liver disease, the function of the future liver remnant, body habitus, overall health, and organ availability. The surgeons also review various surgical approaches to liver resection and recent advancements in liver transplantation, including living donor transplants and the ability to refer patients for downstaging procedures. Dr. Padia explains the original role of Y90 as a bridging treatment to downstage tumors and promote hypertrophy in the non-diseased liver segments, preparing the organ for surgical resection. However, Y90 treatment can also lead to the formation of adhesions, which may complicate future surgeries. Finally, the doctors discuss strategies to improve care coordination between community physicians and transplant centers to optimize patient outcomes. --- TIMESTAMPS 00:00 - Curative vs. Palliative Treatment 04:03 - Choosing Between Transplantation and Resection 05:47 - Liver Resection Types 07:27 - Bridging Role of Y90 12:14 - Evolving Landscape of Liver Transplantation 20:59 - Patient Counseling in Minimally Invasive Procedures 28:40 - Considerations for Surgery After Y90 33:32 - Coordination Between Specialists 40:08 - Immunotherapy as a Bridge to Transplant --- RESOURCES CME Accreditation Information: https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf

I can't believe it took me this long to get Matt Warder on the podcast. But here we are. Matt is the smartest guy in the coal space, and it's not even close. We chat HCC's latest investor presentation, why coal stocks are cheap, the 2026-2027 setup, and Matt's thoughts on precious metals. We finish the conversation with lessons from Matt's dinner with Mohnish Pabrai. MitimcoThis episode is brought to you by MIT Investment Management Company, also known as MITIMCo, the investment office of MIT. Each year, MITIMCo invests in a handful of new emerging managers who it believes can earn exceptional long-term returns in support of MIT's mission. To help the emerging manager community more broadly, they created ⁠⁠⁠⁠⁠⁠⁠⁠⁠emergingmanagers.org⁠⁠⁠⁠⁠⁠⁠⁠⁠, a website for emerging manager stockpickers.For those looking to start a stock-picking fund or just looking to learn about how others have done it, I highly recommend the site. You'll find essays and interviews by successful emerging managers, service providers used by MIT's own managers, essays MITIMCo has written for emerging managers and more!TegusTegus has the world's largest collection of instantly available interviews on all the public and private companies you care about. Tegus actually makes primary research fun and effortless, too. Instead of weeks and months, you can learn a new industry or company in hours, and all from those that know it best.I spend nearly all my time reading Tegus calls on existing holdings and new ideas. And I know you will too. So if you're interested, head on over to ⁠⁠⁠⁠⁠⁠⁠⁠⁠tegus.co/valuehive⁠⁠⁠⁠⁠⁠⁠⁠⁠ for a free trial to see for yourself.TIKRTIKR is THE BEST resource for all stock market data, I use TIKR every day in my process, and I know you will too. Make sure to check them out at ⁠⁠⁠⁠⁠⁠⁠⁠⁠TIKR.com/hive⁠⁠⁠⁠⁠⁠⁠⁠⁠.

The process of liver transplantation involves many complexities, and each patient's path to transplant is unique. To offer insider perspectives on this process, Dr. Zachary Berman sits down with transplant and hepatobiliary surgeon Dr. John Seal, as well as transplant hepatologists Dr. Heather Patton and Dr. Steve Young. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125740 --- This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific. --- SYNPOSIS The panel begins by discussing the multidisciplinary pre-transplant evaluation process, which assesses factors such as liver function, comorbidities, surgical risk, and the availability of psychosocial support. Once a patient is listed for transplant, they enter a system that prioritizes those with the highest Model for End-Stage Liver Disease (MELD) score. During the waiting period, several comorbidities should be carefully monitored. Dr. Seal explores the impact of portal vein hypertension and portal vein thrombosis, explaining how these conditions may necessitate intraoperative thrombectomy or bypass. Dr. Patton and Dr. Young focus on considerations for using anticoagulation in patients with a high baseline bleeding risk and selecting the appropriate anticoagulant for patients listed for transplant. For patients with hepatocellular carcinoma (HCC), eligibility for MELD exception points may depend on factors such as time spent on the waiting list, adherence to the Milan criteria, and the presence of extrahepatic complications of liver disease. The panel also discusses bridging therapies to transplant, including Y90 and TACE. In the peri-transplant phase, they highlight innovations such as living donor transplants, liver perfusion pumps, and the use of hepatitis C- and HIV-positive organs. Finally, the discussion turns to post-transplant considerations, including surgical complications, organ rejection, immunosuppression, predictors of HCC recurrence, and long-term surveillance. --- TIMESTAMPS 00:00 - Introduction 01:16 - Current Landscape of Liver Transplantation 03:22 - Transplant Evaluation Process 09:48 - Timeline from Listing to Transplantion 11:16 - Treating Portal Vein Thrombosis and Hypertension 18:44 - MELD Exception Points 22:05 - Bridging Therapies 25:34 - Peri-Transplant Considerations 30:53 - Post-Transplant Period 37:39 - Repeat Transplantation --- RESOURCES Model for end-stage liver disease (MELD) and allocation of donor livers (Wiesner et al, 2003): https://www.gastrojournal.org/article/S0016-5085%2803%2950022-1/fulltext Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis- Milan Criteria (Mazzaferro et al, 1996): https://pubmed.ncbi.nlm.nih.gov/8594428/ Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database (Mehta et al, 2019): https://pmc.ncbi.nlm.nih.gov/articles/PMC6445634/ CME Accreditation Information: https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf

Treatment of hepatocellular carcinoma (HCC), like that of many other cancers, spans a spectrum from curative to palliative intent. To explore the "grey zone" of treatment goals for intermediate-stage HCC patients, Dr. Sabeen Dhand interviews a panel of experts in the field: medical oncologists Dr. Adam Burgoyne and Dr. Lingling Du, along with interventional radiologists Dr. Kirema Garcia-Reyes and Dr. Zachary Berman. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125739 --- This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific. --- SYNPOSIS The discussion begins with an explanation of the Barcelona-Clinic Liver Cancer (BCLC) staging system. While this system takes into account helpful factors such as liver function, performance status, and tumor burden, it fails to fully capture the true heterogeneity of the HCC patient population. Additional considerations include tumor biology, response to previous treatments, and the location of metastases. The specialists then share their experiences in treating patients with comorbid gastrointestinal cancers and mixed tumors, discuss the benefits of an interventional oncology clinic setting, and highlight virtual opportunities for connecting with tumor boards. They also offer advice on patient education regarding treatment options. --- TIMESTAMPS 00:00 - Introduction to BCLC Staging 03:02 - Impact of Performance Status 06:29 - Predictors of Survival in HCC 09:51 - Palliative versus Curative Treatment Intent 13:55 - Comorbid and Mixed Gastrointestinal Cancers 16:51 - Adverse Effects of Treatment 20:37 - Interventional Oncology in the Clinic Setting 23:06 - Navigating Multiple Provider Viewpoints 28:01 - Complex Case Examples --- RESOURCES BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update (Reig et al, 2022): https://www.journal-of-hepatology.eu/article/S0168-8278(21)02223-6/fulltext CME Accreditation Information: https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf

Featuring perspectives from Dr Anthony El-Khoueiry, Dr Richard S Finn, Dr Aiwu Ruth He and Dr Stacey Stein, moderated by Dr Stephen “Fred” Divers, including the following topics: Adjuvant Systemic Therapy for Early-Stage Hepatocellular Carcinoma (HCC) — Dr El-Khoueiry Introduction (0:00) Faculty Presentation (3:08) IMbrave050: Adjuvant systemic treatment for high-risk resected HCC — Robin K (Katie) Kelley, MD and Thomas A Abrams, MD (13:43) Neoadjuvant systemic therapy for patients with borderline resectable HCC — Dr Abrams (20:15) Case: A man in his early 70s with locally advanced HCC and tumor thrombus that extends into the right atrium — Ghassan Abou-Alfa, MD, MBA (24:34) Recent Developments in the Management of Intermediate-Stage HCC — Dr Finn  Faculty Presentation (31:18) EMERALD-1 and LEAP-012 trials of TACE with immunotherapy — Drs Abrams and Kelley (42:15) Systemic treatment for patients with Child-Pugh B cirrhosis and HCC — Dr Kelley (48:29) Use of immunotherapy for patients with autoimmune disorders: A man in his early 30s with active colitis and metastatic HCC receives first-line lenvatinib — Drs Abrams and Abou-Alfa (53:05) Current First-Line Therapy for Advanced HCC — Dr He Faculty Presentation (1:00:39) Selection of first-line treatment regimen for advanced HCC — Drs Abrams, Kelley and Abou-Alfa (1:12:00) Role of single-agent immunotherapy in the treatment of advanced HCC — Dr Kelley (1:18:22) Management of HCC in patients with discordant tumor markers or mixed tumor histology — Dr Abrams (1:23:03) Promising Investigational Front-Line Strategies for Advanced HCC; Selection and Sequencing of Therapy for Relapsed/Refractory HCC — Dr Stein  Faculty Presentation (1:29:42) Choice of tyrosine kinase inhibitor as second-line systemic treatment for HCC; prevention, monitoring and mitigation of lenvatinib-associated side effects — Dr Kelley (1:42:59) Case: A man in his early 70s with metastatic HCC that has rapidly progressed on atezolizumab/bevacizumab — Dr Abou-Alfa (1:49:27) Supportive care measures to manage ascites in patients with HCC — Dr Abrams (1:55:20) CME information and select publications

SummaryIn this conversation, the panel discusses the complexities and challenges faced by external auditors in the healthcare industry. They explore the importance of maintaining integrity and ethical standards while navigating client relationships, compliance issues, and the business side of medicine. The discussion highlights the need for clear communication and understanding between auditors and healthcare providers to ensure proper documentation and adherence to regulations. The conversation delves into various aspects of healthcare compliance, focusing on HCC chart reviews, the integrity of medical records, and the complexities of transitional care management (TCM). The participants discuss the importance of understanding medical necessity, the role of digital e-visits, and the risks associated with vendor relationships in healthcare. They emphasize the need for accurate documentation, the challenges faced by providers, and the importance of compliance in billing practices.TakeawaysExternal auditors play a crucial role in healthcare compliance.Clients often want validation rather than objective feedback.Maintaining integrity is essential in consulting roles.Documentation must support billing to avoid compliance issues.Providers need to understand the business side of medicine.Ethical standards should not be compromised for profit.Communication is key in client-auditor relationships.Preventative services should not incur out-of-pocket costs for patients.Auditors must navigate gray areas in compliance guidance.The importance of philosophical alignment in consulting engagements. HCC chart reviews are crucial for identifying missing information.Metadata manipulation in medical records can lead to compliance issues.Transitional Care Management (TCM) is essential for patient support post-discharge.Providers often misunderstand the billing process for TCM services.Medical necessity must be clearly documented and justified.Digital e-visits offer a new avenue for patient-provider communication.Vendors can create compliance risks if not properly vetted.Healthcare providers need to be aware of the implications of coding errors.Consultants play a vital role in ensuring compliance and proper documentation.Coders must actively correct and verify the accuracy of medical records.

In this episode Dr. Refky Nicola explores the latest updates to LIRADS Ultrasound Surveillance 2024 with guest Dr. Aya Kamaya. Focusing on its role in hepatocellular carcinoma (HCC) screening and how it compares to other imaging modalities. Key topics include the importance of surveillance, the benefits and limitations of ultrasound, and new guidelines for improving early HCC detection. LI-RADS US Surveillance Version 2024 for Surveillanceof Hepatocellular Carcinoma: An Update to the American Collegeof Radiology US LI-RADS. Kamaya et al. Radiology 2024; 313(3):e240169.

For hepatocellular carcinoma (HCC) patients who are not candidates for liver transplant or resection, lesion ablation can be a curative treatment. With multiple ablation options available and still under investigation, it can be challenging to navigate the differences between them. In this episode, Dr. Tyler Sandow hosts a discussion with interventional radiologists Dr. Kirema Garcia-Reyes, Dr. Sabeen Dhand, and Dr. Kevin Burns on the various ablation options for HCC and when to use each one. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125738" --- This podcast is supported by an educational grant from: AstraZeneca https://www.astrazeneca.com/our-therapy-areas/oncology.html With additional support from: Boston Scientific https://www.bostonscientific.com/en-US/medical-specialties/interventional-radiology/interventional-oncology.html --- SYNPOSIS The doctors first discuss Barcelona-Clinic Liver Cancer (BCLC) Stage A patients, where lesion size and location are key factors in deciding between ablation and transarterial therapies. They then compare cryoablation and microwave ablation, highlighting that cryoablation offers better visualization and control of the ablation zone, while microwave ablation is more effective for treating larger lesions. Dr. Burns introduces histotripsy, a noninvasive treatment that uses ultrasound energy to mechanically ablate tumors. He shares his experiences as an early adopter of this technology and discusses how intraoperative cone beam CT can help treat lesions located near critical structures or those poorly visualized on ultrasound. Finally, Dr. Garcia-Reyes and Dr. Berman provide insights into patient selection, pre-procedural imaging, and technical tips for Y90. --- TIMESTAMPS 00:00 - Introduction 02:04 - Ablation vs Y90 in BCLC A Patients 05:58 - Same-Day Y90 15:55 - Y90 for Large Tumors 17:51 - Ideal Cases for Cryoablation 19:38 - Explanation of Histotripsy 32:09 - Procedural Specifics for Histotripsy 38:21 - Technical Tips for Y90 --- RESOURCES Including the Hollow Viscera (Stomach or Bowel) within the Ice Ball during Cryoablation: A Review of Adverse Events (Abramyan et al, 2024): https://www.jvir.org/article/S1051-0443(24)00681-X/abstract

In the past five years, the use of immunotherapeutic agents for advanced cancers has emerged as a promising alternative to tyrosine kinase inhibitors and chemotherapy, making it an exciting time to be practicing oncology. In this episode, Dr. Tyler Sandow interviews oncology experts about the landscape of advanced hepatocellular carcinoma (HCC) and the current state of immunotherapy treatments. He is joined by medical oncologists Dr. Jonathan Mizrah, Dr. Lingling Du, and Dr. Adam Burgoyne, as well as interventional oncologist Dr. Zachary Berman. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125737 --- This podcast is supported by an educational grant from: AstraZeneca https://www.astrazeneca.com/our-therapy-areas/oncology.html With additional support from: Boston Scientific https://www.bostonscientific.com/en-US/medical-specialties/interventional-radiology/interventional-oncology.html --- SYNPOSIS Drs. Burgoyne and Mizrahi provide a primer on immunotherapy and explain how they communicate the principles of this treatment to their patients. Dr. Du discusses the Imbrave clinical trial and how recent studies have shown improved overall survival when immunotherapeutic agents are used, especially when multiple agents targeting various pathways are employed. When choosing between different regimens, the doctors consider factors such as the patient's underlying liver function, symptom burden, and prior treatments. Importantly, the doctors also discuss contraindications to immunotherapy, including a history of organ transplant, autoimmune disease, and poor performance status—all of which put patients at high risk for deterioration with this treatment. The treatment of patients with poor liver function remains controversial, as underlying cirrhosis may prevent the recovery of liver function. Dr. Berman outlines recent clinical trials studying the effects of transarterial chemoembolization (TACE) combined with immunotherapy. Finally, the doctors discuss the future of HCC treatment and the benefits of continued innovation in both interventional and medical oncology. --- TIMESTAMPS 00:00 - Introduction to Immunotherapy 04:32 - Notable Clinical Trials 13:39 - HCC Etiology and Immunotherapy Outcomes 18:43 - Contraindications for Immunotherapy 23:05 - Adverse Effects from Treatment 25:14 - Combination Therapy 36:22 - Considerations for Immunotherapy Dosing 40:26 - The Future of HCC Treatment --- RESOURCES Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma, IMbrave150 Trial (Finn et al, 2020): https://pubmed.ncbi.nlm.nih.gov/32402160/ Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma, HIMALAYA Trial (Abou-Alfa et al, 2022): https://evidence.nejm.org/doi/full/10.1056/EVIDoa2100070 Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial (Yau, 2022): https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00604-5/abstract Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW (Galle, 2024): https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA4008 Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment (Llovet, 2022): https://pubmed.ncbi.nlm.nih.gov/35119481/ Find this episode on BackTable.com for more resources.